Figure 7.

Mechanistic model to show how MEQ inhibits triple-negative breast cancer (TNBC) angiogenesis by regulating the MTA2/SerRS/VEGFA axis. The MTA2-containing NuRD deacetylase complex binds to the SerRS promoter to suppress its transcription, which allows more SerRS competitor, i.e., c-Myc proteins, to bind to the VEGFA promoter and activate VEGFA expression and tumor angiogenesis. MEQ interacts with MTA2 and may cause the release of the NuRD complex from the SerRS promoter, resulting in elevated expression of SerRS, which competes off the c-Myc and binds to the VEGFA promoter to suppress its transcription and inhibit tumor angiogenesis.